Literature DB >> 12456078

Recent developments in the pathology of Parkinson's disease.

K A Jellinger1.   

Abstract

Parkinson's disease (PD) is morphologically characterized by progressive loss of neurons in the substantia nigra pars compacta (SNpc) and other subcortical nuclei associated with intracytoplasmic Lewy bodies and dystrophic (Lewy) neurites mainly in subcortical nuclei and hippocampus und, less frequently in cerebral cortex. SN cell loss is significantly related to striatal dopamine (DA) deficiency as well as to both the duration and clinical severity of disease, The two major clinical subtypes of PD show different morphologic lesion patterns: the akinetic-rigid form has more severe cell loss in the ventrolateral part of SN with negative correlation to DA loss in the posterior putamen, and motor symptoms related to overacitivty of the GABAergic "indirect" motor loop, which causes inhibition of the glutamatergic thalamocortical pathway and reduced cortical activation. The tremor-dominant type shows more severe cell loss in the medial SNpc and retrorubal field A 8, which project to the matrix of the dorsolateral striatum and ventromedial thalamus, thus causing hyperactivity of thalamomotor and cerebellar projections. These and experimental data suggesting different pathophysiological mechanisms for the major clinical subtypes of PD may have important therapeutic implications. Lewy bodies, the morphologic markers of PD, are composed of hyperphosphorylated neurofilament proteins, lipids, redox-active iron, ubiquitin, and alpha-synuclein, showing a continuous accumulation in the periphery and of ubiquitin in the central core. Alpha-synuclein, is usually unfolded in alpha-helical form. By gene mutation, environmental stress or other factors it can be transformed to beta-folding which is sensible to self-aggregation in filamentous fibrils and formation of insoluble intracellular inclusions that may lead to functional disturbances and, finally, to death of involved neurons. While experimental and tissue culture studies suggest that apoptosis, a genetically determined form of programmed cell death, represents the most common pathway in neurodegeneration, DNA fragmentation, overexpression of proapoptotic proteins and activated caspase-3, the effector enzyme of the terminal apopoptic cascade, have only extremely rarely been detected in SN of PD brains. This is in accordance with the rapid course of apoptotis and the extremely slow progression of the neurodegenerative process in PD. The biological role of Lewy bodies and other intracellular inclusions, the mechanisms of the intracellular aggregation of insoluble protein deposits, and their implication for cellular dysfunction resulting in neurodegeneration and cell demise are still unresolved. Further elucidation of the basic molecular mechanisms of cytoskeletal lesions will provide better insight into the pathogenesis of neurodegeneration in PD and related disorders.

Entities:  

Mesh:

Year:  2002        PMID: 12456078     DOI: 10.1007/978-3-7091-6139-5_33

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  36 in total

1.  Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.

Authors:  Carrie K Jones; Darren W Engers; Analisa D Thompson; Julie R Field; Anna L Blobaum; Stacey R Lindsley; Ya Zhou; Rocco D Gogliotti; Satyawan Jadhav; Rocio Zamorano; Jim Bogenpohl; Yoland Smith; Ryan Morrison; J Scott Daniels; C David Weaver; P Jeffrey Conn; Craig W Lindsley; Colleen M Niswender; Corey R Hopkins
Journal:  J Med Chem       Date:  2011-10-19       Impact factor: 7.446

Review 2.  Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.

Authors:  Annalisa Pinna
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

3.  The impact of ventrolateral thalamotomy on tremor and voluntary motor behavior in patients with Parkinson's disease.

Authors:  Christian Duval; Michel Panisset; Antonio P Strafella; Abbas F Sadikot
Journal:  Exp Brain Res       Date:  2005-11-23       Impact factor: 1.972

Review 4.  Nicotinic receptors containing the alpha7 subunit: a model for rational drug design.

Authors:  G Sharma; S Vijayaraghavan
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

5.  Morphological differences in Parkinson's disease with and without rest tremor.

Authors:  David H Benninger; Sebastian Thees; Spyros S Kollias; Claudio L Bassetti; Daniel Waldvogel
Journal:  J Neurol       Date:  2009-02-04       Impact factor: 4.849

6.  Acute exposure to the mitochondrial complex I toxin rotenone impairs synaptic long-term potentiation in rat hippocampal slices.

Authors:  Ryoichi Kimura; Lu-Yao Ma; Chen Wu; Dharshaun Turner; Jian-Xin Shen; Kevin Ellsworth; Makoto Wakui; Marwan Maalouf; Jie Wu
Journal:  CNS Neurosci Ther       Date:  2012-05-22       Impact factor: 5.243

Review 7.  Cognitive impairment and dementia in patients with Parkinson disease.

Authors:  James B Leverenz; Joseph F Quinn; Cyrus Zabetian; Jing Zhang; Kathleen S Montine; Thomas J Montine
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

8.  Motor imagery evokes increased somatosensory activity in Parkinson's disease patients with tremor.

Authors:  Rick C Helmich; Bastiaan R Bloem; Ivan Toni
Journal:  Hum Brain Mapp       Date:  2011-06-14       Impact factor: 5.038

9.  Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis.

Authors:  Ping Liu; Tao Feng; Yong-jun Wang; Xuan Zhang; Biao Chen
Journal:  J Zhejiang Univ Sci B       Date:  2011-09       Impact factor: 3.066

10.  Nicotinic Receptors: Role in Addiction and Other Disorders of the Brain.

Authors:  Geeta Sharma; Sukumar Vijayaraghavan
Journal:  Subst Abuse       Date:  2008-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.